Home ›
Lymphoma Trials ›
NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Trial Details
NCT ID NCT06350318
Phase PHASE2
Sponsor H. Lee Moffitt Cancer Center and Research Institute
Status RECRUITING
Cancer Type Lymphoma
Interventions
Locations (sample) Tampa, Florida, United States|27.94752,-82.45843
Key Eligibility Criteria
Cohort A: Previously untreated MZL. Prior therapy with H. Pylori antibiotic therapy or hepatitis C antiviral therapy are allowed on Cohort A. Cohort B: Previously untreated FL Pathological confirmation of lymphoma: availability of archival tissue confirming diagnosis of MZL (cohort A) or FL (cohort B). Availability of for… MZL (Cohort A):
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →